News
Exicure, Inc. (Nasdaq: XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback